Search

Displaying results 2711 - 2720 of 10000 in total
  1. Drug

    Aurothioglucose

    go.drugbank.com/drugs/DB09121
    ApprovedWithdrawn

    Aurothioglucose, also known as gold thioglucose, was formerly used to treat rheumatoid arthritis. … The use of gold compounds has decreased since the 1980s owing to numerous side effects, limited efficacy, and slow onset of action.

  2. Drug

    Sodium chlorite

    go.drugbank.com/drugs/DB13210
    Investigational

    Used as an agent for cleaning drinking water. It is also used as an additive in products like toothpaste and mouthwash. Acidified sodium chlorite was approved by the U.S. … Food and Drug Administration as of 2004, as an anti-microbial agent which is non-toxic, but not as a drug [A174811, L5413].

    Mixtures: Av-1000Categories: Preparations for Treatment of Wounds and Ulcers
  3. Drug

    Isavuconazonium

    go.drugbank.com/drugs/DB06636
    ApprovedInvestigational

    This formulation also avoids the use of a cyclodextrin vehicle for solubilization required for intravenous administration of other antifungals such as voriconazole and posaconazole, eliminating concerns … Isovuconazonium has excellent oral bioavailability, predictable pharmacokinetics, and a good safety profile, making it a reasonable alternative to its few other competitors on the market.

  4. Drug

    Azlocillin

    go.drugbank.com/drugs/DB01061
    Approved

    Azlocillin is a semisynthetic ampicillin-derived acylureido penicillin.

    Categories: combinations of penicillins
  5. Drug

    Voclosporin

    go.drugbank.com/drugs/DB11693
    ApprovedInvestigational

    [L31208] Voclosporin has demonstrated a more stable pharmacokinetic and pharmacodynamic relationship than cyclosporine, a higher potency than cyclosporine, and an improved metabolic profile when compared … [A227683] Voclosporin, marketed as Lupkynis, is a calcineurin-inhibitor immunosuppressant for the treatment of LN.

  6. Drug

    Acetophenazine

    go.drugbank.com/drugs/DB01063
    Approved

    Acetophenazine is an antipsychotic drug of moderate-potency. It is used in the treatment of disorganized and psychotic thinking.

  7. Drug

    Catumaxomab

    go.drugbank.com/drugs/DB06607
    ApprovedWithdrawn

    Its market authorization was withdrawn in the EU in June 2017 at the manufacturer's request due to the company's insolvency. … Catumaxumab is a trifunctional monoclonal antibody developed for use in cancer treatment. It has affinity for T-cells, accessory immune cells, and cancer cells.

  8. Drug

    Influenza B virus B/Phuket/3073/2013 hemagglutinin antigen (formaldehyde inactivated)

    go.drugbank.com/drugs/DB14407
    ApprovedInvestigational

    Vaccines provide protection from influenza by exposing the immune system to the virus (or parts of the virus) which stimulates an immunological defence against future exposure to the virus, or "antigen … A seasonally-specific component of the influenza vaccine. The influenza vaccine, also known as the "flu shot", is a vaccine that protects against infection from the influenza viruses.

    Mixtures: VAXİGRİP 0,5 ML IM/SC ENJEKSİYON İÇİN SÜSPANSİYON İÇEREN KULLANIMA HAZIR ENJEKTÖR , 10 ADET, VAXİGRİP TETRA 0,5 ML IM/SC ENJEKSİYON İÇİN SÜSPANSİYON İÇEREN KULLANIMA HAZIR ENJEKTÖR , 1 ADET
  9. Drug

    Besilesomab

    go.drugbank.com/drugs/DB13979
    Approved

    Utilised only as a diagnostic agent, besilesomab is currently approved by the EMEA for marketing and use in various European countries like Italy, France, Germany, Spain, Portugal, Norway, Sweden, the … Besilesomab is a mouse monoclonal antibody labelled with the radioactive isotope technetium-99m for determining the location of inflammation/infection in peripheral bone in adults with suspected osteomyelitis

  10. Drug

    Sodium zirconium cyclosilicate

    go.drugbank.com/drugs/DB14048
    ApprovedInvestigational

    Sodium zirconium cyclosilicate is approved as the trade product Lokelma developed by AstraZeneca - an insoluble, non-absorbed sodium zirconium silicate, formulated as a powder for oral suspension that … the median time to achieving normal potassium levels in the blood was 2.2 hours, with 92% of patients achieving normal potassium levels within 48 hours following administration.

    Categories: Compounds used in a research, industrial, or household setting, Drugs for Treatment of Hyperkalemia and HyperphosphatemiaProducts: SIMKELMA 5 G ORAL SÜSPANSİYON HAZIRLAMAK İÇİN TOZ, 28 ADET, SIMKELMA 10 G ORAL SÜSPANSİYON HAZIRLAMAK İÇİN TOZ, 28 ADET